Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
One of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously bindin...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2025-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1769 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849339186420645888 |
|---|---|
| author | A. L. Maslyanskiy D. A. Dibrov A. M. Lila A. V. Torgashina E. G. Zotkin M. Yu. Samsonov G. A. Togizbayev |
| author_facet | A. L. Maslyanskiy D. A. Dibrov A. M. Lila A. V. Torgashina E. G. Zotkin M. Yu. Samsonov G. A. Togizbayev |
| author_sort | A. L. Maslyanskiy |
| collection | DOAJ |
| description | One of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously binding multiple antigens, making them a promising platform for novel drugs. A specific type of such agent, which incorporates at least two antigen-binding (Fab) fragments within a single immunoglobulin molecule – one targeting a specific cell-surface receptor and the other binding and activating to the CD3ε domain of CD3 molecule of the T-cell receptor complex – has been termed a bispecific T-cell engager (BiTE).Currently, BiTE molecules that engage effector cells of the humoral immune system are the most clinically advanced subclass of bsAbs. Their ability to deplete target cells in peripheral blood and tissues has been clearly demonstrated in the treatment of resistant hematological malignancies such as B-cell precursor acute lymphoblastic leukemia, various lymphoproliferative disorders, and plasma cell dyscrasias. Recent years have seen attempts to repurpose bsAbs for the treatment of refractory, prognostically unfavorable forms of systemic autoimmune rheumatic diseases (SARDs), supported by theoretical rationale, experimental evidence, and parallels with successful CAR-T cell therapy.Beyond BiTEs, the bsAb platform also enables development of biologics with extended pharmacokinetics, multi-cytokine targeting potential for synergistic suppression of inflammation, and checkpoint-directed modulation of targeted cell functional activity.Advantages such as standardized manufacturing, off-the-shelf availability, predictable pharmacokinetics (with a known and limited half-life), flexible dosing regimens enabling slow escalation of the dose, the possibility of individualizing treatment duration and dosing frequency, the feasibility of repeated treatment cycles, the option to discontinue therapy in case of adverse events, and the significantly lower cost of short low-dose treatment cycles compared to CAR-T cell therapy – all these make bsAb-based strategies a highly attractive priority for next-generation depletion-restitution therapies for SARDs. |
| format | Article |
| id | doaj-art-223b31abdcf0457c8d543edaee3d30a1 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2025-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-223b31abdcf0457c8d543edaee3d30a12025-08-20T03:44:11ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2025-06-0119371810.14412/1996-7012-2025-3-7-182786Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodiesA. L. Maslyanskiy0D. A. Dibrov1A. M. Lila2A. V. Torgashina3E. G. Zotkin4M. Yu. Samsonov5G. A. Togizbayev6V.A. Nasonova Research Institute of Rheumatology ; Almazov National Medical Research Centre, Ministry of Health of Russia ; St Petersburg State UniversityV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyR-Pharm JSCKazakh National Medical University named after S.D. AsfendiyarovOne of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously binding multiple antigens, making them a promising platform for novel drugs. A specific type of such agent, which incorporates at least two antigen-binding (Fab) fragments within a single immunoglobulin molecule – one targeting a specific cell-surface receptor and the other binding and activating to the CD3ε domain of CD3 molecule of the T-cell receptor complex – has been termed a bispecific T-cell engager (BiTE).Currently, BiTE molecules that engage effector cells of the humoral immune system are the most clinically advanced subclass of bsAbs. Their ability to deplete target cells in peripheral blood and tissues has been clearly demonstrated in the treatment of resistant hematological malignancies such as B-cell precursor acute lymphoblastic leukemia, various lymphoproliferative disorders, and plasma cell dyscrasias. Recent years have seen attempts to repurpose bsAbs for the treatment of refractory, prognostically unfavorable forms of systemic autoimmune rheumatic diseases (SARDs), supported by theoretical rationale, experimental evidence, and parallels with successful CAR-T cell therapy.Beyond BiTEs, the bsAb platform also enables development of biologics with extended pharmacokinetics, multi-cytokine targeting potential for synergistic suppression of inflammation, and checkpoint-directed modulation of targeted cell functional activity.Advantages such as standardized manufacturing, off-the-shelf availability, predictable pharmacokinetics (with a known and limited half-life), flexible dosing regimens enabling slow escalation of the dose, the possibility of individualizing treatment duration and dosing frequency, the feasibility of repeated treatment cycles, the option to discontinue therapy in case of adverse events, and the significantly lower cost of short low-dose treatment cycles compared to CAR-T cell therapy – all these make bsAb-based strategies a highly attractive priority for next-generation depletion-restitution therapies for SARDs.https://mrj.ima-press.net/mrj/article/view/1769depletion therapydepletion-restitution therapyb-cellsplasma cellsbispecific antibodiesmonoclonal antibodies |
| spellingShingle | A. L. Maslyanskiy D. A. Dibrov A. M. Lila A. V. Torgashina E. G. Zotkin M. Yu. Samsonov G. A. Togizbayev Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies Современная ревматология depletion therapy depletion-restitution therapy b-cells plasma cells bispecific antibodies monoclonal antibodies |
| title | Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies |
| title_full | Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies |
| title_fullStr | Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies |
| title_full_unstemmed | Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies |
| title_short | Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies |
| title_sort | depletion restitution therapy of autoimmune rheumatic diseases part 2 perspectives on bispecific antibodies |
| topic | depletion therapy depletion-restitution therapy b-cells plasma cells bispecific antibodies monoclonal antibodies |
| url | https://mrj.ima-press.net/mrj/article/view/1769 |
| work_keys_str_mv | AT almaslyanskiy depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies AT dadibrov depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies AT amlila depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies AT avtorgashina depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies AT egzotkin depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies AT myusamsonov depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies AT gatogizbayev depletionrestitutiontherapyofautoimmunerheumaticdiseasespart2perspectivesonbispecificantibodies |